Racetam nootropic
Aniracetam
Aniracetam's plasma half-life was 0.47 to 0.49 hours in a single-dose study of 20 healthy men, while the app lists 2 hours.1
Aniracetam after one dose: 50% at ~2 h, 25% at 4 h, 12.5% at 6 h.
Drawn from the half-life in the app's model, ~2 h. The model's figures
- Compound
- Aniracetam
- Symbol
- ANI
- Family
- Supplements
- Parts
- 12
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
Aniracetam is a racetam, a pyrrolidinone-type cognition enhancer, which Nakamura (CNS Drug Reviews, 2002) describes as "clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease".2 Nakamura's affiliation is the Department of Product Research, Nippon Roche Research Center, Japan.2 The review states that "there is no convincing evidence that promising effects of aniracetam in the animal models will guarantee its clinical efficacy".2
In Italy, an Italian-language product summary reproducing AIFA text for Ampamet (aniracetam, Menarini) gives the indication as attention and memory disorders of the elderly "di origine degenerativa o vascolare" (of degenerative or vascular origin).3 It gives 20 August 1993 as the date of first authorisation.3 The website that hosts that text states that it could not find the medicine in the current AIFA list of authorised medicines, and that its text was last updated 21/10/2020.3
The app grades the evidence for aniracetam as moderate. The four efficacy trials retrieved for this review were published between 1987 and 1991: Sourander in 1987, Somnier in 1990, and Senin and Canonico in 1991.4,5,6,7 Searches of PubMed and ClinicalTrials.gov identified no controlled efficacy trial of aniracetam in healthy adults that reports results; the Tian pharmacokinetic crossover study in healthy men and one registry entry from 2026 are described below.1
How it works
Sources in this part
Lee and Benfield (Drugs & Aging, 1994) write that aniracetam "appears to positively modulate metabotropic glutamate receptors and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-sensitive glutamate receptors, and may facilitate cholinergic transmission", effects "possibly related to its mechanism of action".8 The Italian product information describes the same targets, stating that electrophysiological and biochemical studies show it stimulates some glutamate receptors in the central nervous system, specifically the AMPA receptor and the metabotropic receptor, and that it "potenzia la funzione del recettore AMPA" (strengthens the function of the AMPA receptor).3 Nakamura's review reports that several metabolites of aniracetam affected learning and memory in animals and writes that "it is, therefore, conceivable that major metabolites of aniracetam contribute to its pharmacological effects".2 Nakamura's review describes the effects of aniracetam in rodent models and reports the metabolite effects on learning and memory in animals, while the Lee and Benfield review record calls the receptor effects "possibly related to its mechanism of action" without stating the system in which they were seen.8,2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2 h
- Bioavailability
- 80%
- Typical dose
- 750–1500 mg/day
- Route
- Oral
- Time to peak
- ~1 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~2 h | 0.47 ± 0.16 h and 0.49 ± 0.24 h for the test and reference formulation of parent aniracetam in 20 healthy Chinese men after a single 400 mg fasting oral dose; the half-life of its metabolites was increased 4- to 7-fold in six elderly patients with cerebrovascular disease compared with young volunteers1,10 |
| Time to peak | ~1 h | Tmax of 0.4 ± 0.1 h for both formulations of parent aniracetam in the healthy men; serum levels of the metabolites anisic acid and p-methoxyhippuric acid peaked at 2 h in the elderly patients (200 mg dose); the Italian product information gives 5 to 30 minutes for the maximum blood level in animals1,10,3 |
| Bioavailability | 80% | The Italian product information states that oral absorption in people is "rapido e completo" (rapid and complete) and that taking food at the same time does not change the amount absorbed, only its speed; the sources retrieved give no bioavailability percentage3 |
| Metabolites and duration | 4 h (app's duration) | The main metabolite in people is anisoil-GABA (N-anisoyl-GABA, "a major active metabolite of aniracetam"); in animals the main metabolites are described as detectable in blood for 6 to 12 hours; in the six elderly patients, metabolite levels returned to basal by 6 h3,9,10 |
The app lists a half-life of about 2 hours and a time to peak of about 1 hour; the only human measurement of parent aniracetam retrieved gives 0.47 to 0.49 hours and 0.4 hours respectively, so the app's figures are longer than that study's.1 The app's note says active metabolites have a longer half-life; the elderly-patient data compare metabolite half-life with young volunteers (4- to 7-fold longer) and give no comparison with the parent compound.10
Deeper analysis: the Tian single-dose study
Tian and colleagues, of the Key Laboratory of Drug Quality Control and Pharmacovigilance at China Pharmaceutical University, reported in Arzneimittel-Forschung in 2008 what they describe as the first investigation of aniracetam pharmacokinetics in Chinese healthy male volunteers.1 Twenty men took part in an "open, randomized, single blind two-sequence, two-period crossover study", each receiving a single oral dose of 400 mg (2 x 200 mg capsules) as a test or reference formulation under fasting conditions, with a 3-day washout between them.1 Cmax was 8.75 ± 7.82 and 8.65 ± 8.70 ng/mL for the test and reference formulations, and AUC(0-infinity) was 4.62 ± 6.66 and 4.85 ± 6.71 ng h/mL; the reported standard deviations are large relative to the means.1 The 90% confidence limits for AUC and Cmax "were within the standard bioequivalence range (80%-125% for AUC and Cmax)", and the authors regard the test formulation as bioequivalent to the reference.1 The PubMed record retrieved for the paper lists no adverse event data, no funding statement, no author ties to a sponsor and no stated limitations, so none can be reported here; the record states that dosing was under fasting conditions and reports no food-effect comparison.1
An earlier Japanese study (Endo and colleagues, Department of Geriatrics, National Chubu Hospital, Behavioural Brain Research, 1997) gave aniracetam 200 mg to six female hospitalised patients with cerebrovascular disease, mean age 84.5 years, and compared them with young healthy volunteers.10 Mean creatinine clearance was 20-30 ml/min; Tmax, t1/2 and AUC of the metabolites were larger in the elderly, and the authors report that "no clinical side effects were observed".10 The record does not state a funder or the authors' limitations.10
Human studies
The table lists the human studies retrieved, in order of publication of the efficacy trials, followed by pharmacokinetic studies and one registry entry. The PubMed records for the efficacy trials give limited detail.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Sourander and colleagues, Psychopharmacology 19874 | Randomised, double-blind, placebo-controlled4 | 44 patients with senile dementia of the Alzheimer type4 | Aniracetam 1 g or placebo daily for 3 months4 | Several cognitive tests improved in both groups; "no difference was seen in efficacy between the two treatment groups"; treatment interrupted for confusion in four on aniracetam and one on placebo4 |
| Somnier and colleagues, Psychopharmacology 19905 | Randomised, double-blind, placebo-controlled cross-over5 | 44 subjects with chronic psychosyndrome after long-term exposure to organic solvents5 | Aniracetam 1 g daily for 3 months and placebo for 3 months5 | No effect on overall condition by doctors' or subjects' assessment; 1 of 19 neuropsychological measures favoured aniracetam and another test favoured placebo5 |
| Senin and colleagues, European Neuropsychopharmacology 19916 | Double-blind, randomised, placebo-controlled, multicentre6 | 109 elderly patients with mild to moderate cognitive impairment, probable Alzheimer-type dementia6 | Aniracetam or placebo for 6 months; dose not given in the record6 | Aniracetam group differed significantly from placebo by the end; "Tolerability to aniracetam was excellent"; effect sizes not given in the record6 |
| Canonico and colleagues, Rivista di Neurologia 19917 | Placebo-controlled, indexed as randomised; blinding not stated in the record7 | 60 patients, mean age 69.9 ± 10.3 years, with slight-moderate brain pathology primary or secondary to vascular forms7 | Aniracetam 1500 mg/day by mouth or placebo; assessments at 2 and 4 months7 | Scores improved significantly in the aniracetam group; no statistically considerable change in any test in the placebo group7 |
| Tian and colleagues, Arzneimittel-Forschung 20081 | Randomised, single-blind two-period crossover bioequivalence study1 | 20 healthy Chinese male volunteers1 | Single oral dose of 400 mg, fasting; 3-day washout1 | Half-life 0.47 and 0.49 h; Tmax 0.4 h; formulations bioequivalent1 |
| Endo and colleagues, Behavioural Brain Research 199710 | Clinical pharmacokinetic study compared with young healthy volunteers10 | 6 female hospitalised elderly patients with cerebrovascular disease, mean age 84.5 years10 | Aniracetam 200 mg10 | Metabolite half-life increased 4- to 7-fold; "no clinical side effects were observed"10 |
| Registry entry NCT07852130, ClinicalTrials.gov, status verified 2026-0911 | Randomised, parallel, placebo-controlled, phase 1, basic science11 | 70 healthy adults aged 18 to 35 across placebo and five active conditions, about nine per compound11 | Aniracetam 100, 200 or 300 mg/day before testing; seven assessments over six months11 | Status COMPLETED; the entry states these doses "do not constitute a test of the compound's cognitive efficacy"11 |
Deeper analysis: Senin 1991, the largest efficacy trial retrieved
Senin and colleagues, of the Istituto di Gerontologia e Geriatria at the Università di Perugia, reported in European Neuropsychopharmacology in 1991 a six-month, double-blind, randomised, placebo-controlled study in 109 elderly patients with mild to moderate cognitive impairment who fulfilled NINCDS-ADRDA criteria for probable dementia of the Alzheimer type.6 The groups "were comparable at baseline for demographic and behaviourial parameters and symptomatology", and patients "underwent clinical, behaviourial and psychometric evaluation every other month".6 The authors report that "the aniracetam group differed significantly from the placebo group by the end of the study" and improved significantly against baseline in psychobehavioural parameters, "while in the placebo group a steady deterioration was observed".6 They write that "Tolerability to aniracetam was excellent".6 The PubMed record retrieved gives no dose, no effect sizes or p-values, no numbers of discontinuations or adverse events, no secondary or null results, no funding statement, no author ties to a sponsor and no stated limitations, so none can be reported here.6 Lee and Benfield, in a 1994 review from Adis International (Auckland), state that "Aniracetam 1500 mg/day was significantly more effective than placebo in all tests at 4 and 6 months, and in a further 6-month trial was more effective than piracetam 2400 mg/day in 8 of 18 tests"; the review record does not name the trials behind these results.8 The same review states that "further trials required to confirm its efficacy profile" are needed, and that evidence in cognitive impairment of cerebrovascular origin is "preliminary".8
Deeper analysis: Sourander 1987, a null result in Alzheimer-type dementia
Sourander and colleagues reported in Psychopharmacology in 1987 that 44 patients with senile dementia of the Alzheimer type were "randomly allocated into double-blind treatment with either aniracetam (RO 13-5057) 1 g or placebo daily for 3 months".4 Neurological examinations were done before and after treatment, and psychometric tests before and after 1 and 3 months.4 During treatment "an improvement was seen in several cognitive tests, especially those associated with memory, but this improvement occurred in the placebo as well as in the aniracetam-treated group".4 In clinical evaluation "no difference was seen in efficacy between the two treatment groups".4 Treatment was interrupted because of confusion in four patients on aniracetam and one on placebo.4 The PubMed record retrieved states no funder, no author ties to a sponsor and no limitations.4
Deeper analysis: Somnier 1990, solvent-related psychosyndrome
Somnier and colleagues, of the Department of Neurology at Rigshospitalet, Copenhagen, reported in Psychopharmacology in 1990 a randomised, double-blind, placebo-controlled cross-over study of 44 subjects with chronic psychosyndrome after long-term exposure to organic solvents, with 3 months of aniracetam 1 g daily and 3 months of placebo.5 The authors report that "Neither the doctors' nor the subjects' own assessment of the overall condition indicated that the trial medication had had any effect" and that "No significant changes in neuropsychological symptoms were observed".5 Of 19 neuropsychological test measures, a significant difference favoured aniracetam in one, "a test for constructional ability", while in "another test on visuo-spatial function" a significant result favoured placebo.5 The authors conclude that aniracetam was "ineffective in the treatment of subjects suffering from chronic psychosyndrome after long-term exposure to organic solvents".5 The PubMed record retrieved reports no adverse events and states no funder, no author ties to a sponsor and no limitations.5
The Canonico trial and the registry entry
Canonico and colleagues (Cattedra di Geriatria, Università di Napoli) report that scores improved significantly in the aniracetam group at the first and second control (2 and 4 months) while "no change statistically considerable happened in any test" in the placebo group; the record lists a 1500 mg/day oral dose, 60 patients, and gives no adverse event numbers, funder or limitations.7 The 2026 registry entry NCT07852130 names an individual investigator, Abdulraheem Mohamed Gouda, as lead sponsor and the Reserology Research Foundation as the organisation, and states that the study "was designed to detect only very large effects".11 It describes the study as "placebo-controlled and partially blinded rather than double-blind", with about nine participants per active compound.11 The entry says its aniracetam doses of 100, 200 and 300 mg/day are "approximately 5 to 15 times below published human dosing regimens".11 The entry as retrieved holds no posted results for aniracetam.11
Doses reported in studies and on labels
The app lists a typical dose of 750 to 1500 mg/day by mouth. The table gives the doses reported in the sources, each with its reference.
| Source and setting | Dose and schedule reported | People and length |
|---|---|---|
| Italian product information (Ampamet 750 mg tablets, 1500 mg sachets), label for adults3 | Total of 1.500 mg per day in 1 to 2 administrations; one 1500 mg sachet a day or one 750 mg tablet morning and evening3 | Label text says the therapeutic effect appears after 60 days and becomes clearer after 4 months; not to be used in the paediatric population3 |
| Italian product information, severe renal impairment3 | Daily dose halved ("dimezzare la posologia giornaliera") in severe renal insufficiency (creatinine clearance below 10 mL/min)3 | Label text states this for patients with severe renal insufficiency3 |
| Canonico 19917 | 1500 mg/day by mouth versus placebo7 | 60 patients, mean age 69.9 years; assessed at 2 and 4 months7 |
| Sourander 19874 | 1 g daily versus placebo4 | 44 patients with Alzheimer-type dementia; 3 months4 |
| Somnier 19905 | 1 g daily versus placebo, cross-over5 | 44 subjects after solvent exposure; 3 months per period5 |
| Lee and Benfield review 19948 | 1500 mg/day versus placebo; 1500 mg/day versus piracetam 2400 mg/day8 | Trials of 4 to 6 months in elderly patients with cognitive impairment, as summarised by the review8 |
| Tian 20081 | Single 400 mg oral dose (2 x 200 mg), fasting1 | 20 healthy Chinese men; 3-day washout between formulations1 |
| Endo 199710 | Single 200 mg dose10 | 6 elderly female patients with cerebrovascular disease10 |
| Registry entry NCT0785213011 | 100, 200 or 300 mg/day before testing11 | Healthy adults aged 18 to 35; six months11 |
The app's range of 750 to 1500 mg/day lines up with the 750 mg tablet and 1500 mg sachet strengths on the Italian label, whose total is 1500 mg per day.3
Side effects reported
The Italian product information states that Ampamet "risulta ben tollerato in tutti i pazienti, anche se molto anziani" (is well tolerated in all patients, including very elderly ones).3 It lists agitation, anxiety, restlessness and insomnia as occasionally reported, and states that these effects subside when the way of administering it is changed.3 It lists epigastric heaviness, headache, drowsiness, asthenia and dizziness as rarely reported.3 The same document lists hypersensitivity to the active ingredient or an excipient as the contraindication, states "Non sono noti casi da sovradosaggio del farmaco" (no cases of overdose are known), and states that clinical experience has shown no drug interactions with other medicines.3 It states that animal studies showed no teratogenic effects, while keeping the general rule of not giving medicines in pregnancy and breastfeeding.3 Among the trials, Sourander reported treatment interruptions for confusion in four of the aniracetam group and one of the placebo group, Senin called tolerability "excellent", and Endo reported no clinical side effects in six elderly patients.4,6,10 Lee and Benfield state that "incidence rates of adverse effects are not yet available" and that "aniracetam does not appear to cause increases in liver enzyme levels".8 The Italian label advises halving the daily dose in severe renal insufficiency (creatinine clearance below 10 mL/min); Endo's patients had a mean creatinine clearance of 20-30 mL/min and metabolite half-lives 4- to 7-fold longer than young volunteers, and the Endo record does not attribute this to kidney function.3,10 The app lists no health markers to monitor and no interaction flags for aniracetam.
Regulatory and anti-doping status
The Italian product information lists Ampamet under marketing authorisation holder A. Menarini Industrie Farmaceutiche Riunite, with first authorisation on 20 August 1993 and most recent renewal on 20 August 2008.3 The website hosting it adds that its AIFA text may not be current and that it could not find the medicine in the current AIFA list of authorised medicines; the text retrieved does not state a prescription class.3 The Italian approval of Ampamet (aniracetam) was revoked in July 2022, after the holder, Menarini, renounced it, for the packs a notice in the Gazzetta Ufficiale lists: 750 mg film-coated tablets and 1500 mg sachets.12 A search of DailyMed on 16 November 2026 for "aniracetam" returned 0 labels, and no FDA or EMA document on aniracetam was retrieved. The app's note describes aniracetam as unscheduled in the US and prescription-only in the EU; the sources retrieved neither confirm nor contradict the US statement, and the only EU-country document retrieved is the Italian one above. The World Anti-Doping Agency's 2026 Prohibited List text retrieved does not name aniracetam; a search of that text for "racetam" returns only fonturacetam [4-phenylpiracetam (carphedon)], which sits in the stimulants class (S6).13 Class S0 of the same list covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use"; the list text does not say whether S0 applies to aniracetam.13
What is not known
Sources in this part
No controlled trial of aniracetam with anxiety or mood as its stated target in people was identified in the PubMed searches run for this review (queries on aniracetam with "randomized controlled trial", "pharmacokinetics" and "adverse effects safety clinical"); verbal fluency appears only as one of the psychometric tests in the Canonico placebo-controlled trial in elderly patients.7 The app's note describes an anxiolytic angle and mood and verbal-fluency effects; the controlled trials retrieved studied dementia, solvent-related psychosyndrome and elderly cognitive impairment. Whether fat improves absorption, as the app's note says, is not addressed by the human data retrieved; the Italian product information states that food changes only the speed of absorption, not the amount.3 No bioavailability percentage, no volume of distribution and no absorption rate constant were retrieved; the app also leaves the latter two blank. The sources give no study of combining aniracetam with choline, which the app's note mentions. Funding, sponsor ties and the authors' own limitations are not stated in any of the PubMed records retrieved for the efficacy trials, and the efficacy trials are 35 to 39 years old. Lee and Benfield state that further trials are required, and Nakamura states that there is no convincing evidence that animal-model effects will guarantee clinical efficacy.8,2
Frequently asked questions
What is the half-life of aniracetam?
How long does aniracetam take to reach its peak level?
What is the bioavailability of aniracetam?
What are the active metabolites of aniracetam?
The main metabolite in people is anisoil-GABA (N-anisoyl-GABA) according to the Italian product information.3 Cai and Wang describe N-anisoyl-GABA as "a major active metabolite of aniracetam", and Endo and colleagues followed anisic acid and p-methoxyhippuric acid as major metabolites in elderly patients.9,10
Is aniracetam banned by WADA?
Is aniracetam approved by the FDA?
A DailyMed search for aniracetam on 16 November 2026 returned 0 labels, and the sources retrieved include no FDA document on its status.
Is aniracetam approved anywhere?
An Italian product summary for Ampamet, reproducing AIFA text, gives 20 August 1993 as the date of first authorisation.3 The hosting website notes that it could not find the medicine in the current AIFA list of authorised medicines.3 A Gazzetta Ufficiale notice records that the Italian approval of Ampamet was revoked in July 2022 for its 750 mg tablet and 1500 mg sachet packs, after Menarini renounced it.12
What side effects has aniracetam been reported to cause?
The Italian product information lists agitation, anxiety, restlessness and insomnia as occasionally reported, and epigastric heaviness, headache, drowsiness, asthenia and dizziness as rarely reported.3 In the Sourander trial, treatment was interrupted for confusion in four patients on aniracetam and one on placebo.4
Has aniracetam improved memory in trials?
Results are mixed: Sourander reported improvement in both aniracetam and placebo groups with no efficacy difference in 44 patients with Alzheimer-type dementia.4 Senin reported a significant difference from placebo at 6 months in 109 patients, Canonico reported improvement in 60 patients, and Somnier reported no effect in 44 subjects after solvent exposure.6,7,5
Guides, tools and comparisons
References
- Tian Y, et al. Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers. Arzneimittelforschung 2008;58(10):497-500. PMID 19025058
- Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev 2002;8(1):70-89. PMID 12070527
- Torrinomedica. Ampamet (aniracetam): scheda tecnica e prescrivibilità, reproducing the AIFA summary of product characteristics (page text last updated 21/10/2020). Italian product information
- Sourander LB, et al. Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent. Psychopharmacology (Berl) 1987;91(1):90-5. PMID 3103163
- Somnier FE, et al. Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents. Psychopharmacology (Berl) 1990;101(1):43-6. PMID 2188276
- Senin U, et al. Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study. Eur Neuropsychopharmacol 1991;1(4):511-7. PMID 1822317
- Canonico V, et al. Efficacy and tolerance of aniracetam in elderly patients with primary or secondary mental deterioration. Riv Neurol 1991;61(3):92-6. PMID 1767242
- Lee CR, Benfield P. Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. Drugs Aging 1994;4(3):257-73. PMID 8199398
- Cai S, Wang L. Determination of aniracetam's main metabolite, N-anisoyl-GABA, in human plasma by LC-MS/MS and its application to a pharmacokinetic study. J Chromatogr B 2012;897:50-4. PMID 22552003
- Endo H, et al. Pharmacokinetic study of aniracetam in elderly patients with cerebrovascular disease. Behav Brain Res 1997;83(1-2):243-4. PMID 9062694
- ClinicalTrials.gov. NCT07852130: Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily Activity. Status verified 2026-09. NCT07852130
- Gazzetta Ufficiale della Repubblica Italiana, Serie Generale, 2 August 2022. Notice 22A04304: revocation, on the holder's renunciation, of the marketing authorisation of Ampamet. Gazzetta Ufficiale notice
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list